Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CYP3A5 Antibodies:
anti-Mouse (Murine) CYP3A5 Antibodies:
anti-Rat (Rattus) CYP3A5 Antibodies:
Go to our pre-filtered search.
Concentrations of aripiprazole, sex, CYP3A5*3 and CYP2D6 (show CYP2D6 Antibodies) were involved in the development of adverse drug reations to aripiprazole
CYP3A5 genetic polymorphism had a significant influence on tacrolimus pharmacological effects in Chinese liver transplantation patients
The metabolites are predominantly catalyzed by CYP3A4 (show CYP3A4 Antibodies) (77% approximately 87%), with a moderate contribution from CYP3A5 (5% approximately 15%) and CYP1A2 (show CYP1A2 Antibodies) (3.7% approximately 7.5%).
The results obtained by CLIA, ECLIA and ACMIA were not affected by CYP3A5 polymorphism.
CYP3A5 Polymorphism is associated with drug resistance in Breast Cancer.
In summary, we explored the effects of CYP3A5*3, UGT2B7 (show UGT2B7 Antibodies)*2, and UGT2B7 (show UGT2B7 Antibodies)*3 variants on steady-state carbamazepine (CBZ) concentrations in 62 epileptic patients. Our study found that the UGT2B7 (show UGT2B7 Antibodies)*2 variant, but not the CYP3A5*3 and UGT2B7 (show UGT2B7 Antibodies)*3 variants, can affect steady-state CBZ concentrations in these patients.
We demonstrate for the first time that the effect of ABCB1 (show ABCB1 Antibodies) diplotype on tacrolimus disposition is dependent on both CYP3A5 and CYP3A4 (show CYP3A4 Antibodies) genotype.
Our meta-analysis identified a positive correlation between CYP3A5 genotypes and tacrolimus pharmacokinetics in pediatric renal-transplant recipients
Younger age, POR (show POR Antibodies)*28 allele, and CYP3A5*3 allele were associated with higher cyclosporine dosing requirements and lower concentration/dose ratio.
Stability of the dose-adjusted trough concentrations achieved using modified-release once-daily tacrolimus, which was clearly influenced by the CYP3A5 polymorphism, may prevent the development of rejection.
This gene,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene. Multiple alternatively spliced transcript variants have been identified for this gene.
cytochrome P450 3A5
, aryl hydrocarbon hydroxylase
, cytochrome P450 HLp2
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5
, cytochrome P450-PCN3
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase